Sugi Predict

Sugi Predict / Compounds / SCHEMBL3146378

SCHEMBL3146378

SCHEMBL3146378

CC(C)(C)OC(=O)N1CCCCC1CCC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.47
▸ PDE8B O95263 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ KDM1A O60341 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CHEK2 O96017 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ EPHX1 P07099 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ PRMT5 O14744 1/20 0.37
▸ OPRD1 P41143 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25218855 1.00 ATM (0.47) ATMPDE8BHSD17B10KDM1ASMN1; SMN2
SCHEMBL25220677 1.00 ATM (0.47) ATMPDE8BHSD17B10KDM1ASMN1; SMN2
SCHEMBL22570262 0.96 HSD17B10 (0.48) ATMPDE8BHSD17B10SMN1; SMN2CHEK2
SCHEMBL5191626 0.96 HSD17B10 (0.48) ATMPDE8BHSD17B10SMN1; SMN2CHEK2
SCHEMBL3441499 0.92 ATM (0.45) ATMPDE8BHSD17B10KDM1ASMN1; SMN2
SCHEMBL25320917 0.90 ATM (0.41) ATMHSD17B10SMN1; SMN2HPGDALDH1A1
SCHEMBL18420105 0.87 PDE8B (0.46) ATMPDE8BHSD17B10KDM1ASMN1; SMN2
SCHEMBL6157710 0.86 ATM (0.47) ATMPDE8BHSD17B10KDM1ASMN1; SMN2
SCHEMBL7989798 0.86 ATM (0.47) ATMPDE8BHSD17B10KDM1ASMN1; SMN2
SCHEMBL26547640 0.86 HSD17B10 (0.45) ATMPDE8BHSD17B10SMN1; SMN2CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163030-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES GILEAD SCIENCES, INC. 2025-05-22 — — US disclosed
CN-118139858-A Pyrazin-3 (2H) -one derivatives 吉利德科学公司 2024-06-04 — — CN disclosed
WO-2024015262-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS, INC. (US) 2024-01-18 — — WO disclosed
US-20230183216-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES GILEAD SCIENCES, INC. 2023-06-15 — — US disclosed
CN-110248949-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2023-02-17 — — CN disclosed
US-11154563-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-10-26 — — US disclosed
EP-3571208-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2021-03-10 — — EP disclosed
US-20190336515-A1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC. 2019-11-07 — — US disclosed
CN-110248949-A Immunoproteasome inhibitor 普林斯匹亚生物制药公司 2019-09-17 — — CN disclosed
CN-106414448-B It can be used as the new compound of S100- inhibitor 活跃生物技术有限公司 2019-04-19 — — CN disclosed
CN-1930182-A Anticoagulant compounds SANOFI AVENTIS (FR) 2007-03-14 — — CN disclosed
EP-1725577-A1 ANTITHROMBOTIC COMPOUND Sanofi-Aventis (FR) 2006-11-29 — — EP disclosed
US-20060264449-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2006-11-23 — — US disclosed
US-20060178359-A1 Tricyclic compound, process for producing the same, and use SYNGENTA CROP PROTECTION AG (CH) 2006-08-10 — — US disclosed
US-20060024330-A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2006-02-02 — — US disclosed
EP-1593681-A1 TRICYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 — — EP disclosed
WO-2005090382-A1 ANTITHROMBOTIC COMPOUND SANOFI-AVENTIS (FR) 2005-09-29 — — WO disclosed
EP-1574516-A1 Antithrombotic compound Sanofi-Aventis (FR) 2005-09-14 — — EP disclosed
EP-1558083-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-08-03 — — EP disclosed
WO-2004034972-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2004-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154563-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 ATM 3485/4885PDE8B 3319/4885HSD17B10 2334/4885
US-20060178359-A1 Tricyclic compound, process for producing the same, and use CCR4, CCR5, CCR1 ATM 3756/4885PDE8B 4803/4885HSD17B10 2112/4885
US-20250163030-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES PIR, CYP3A43, CYP1A2 ATM 2879/4885PDE8B 3915/4885HSD17B10 2713/4885
US-20190336515-A1 IMMUNOPROTEASOME INHIBITORS PSMC2, PSMB7, PSMB2 ATM 3485/4885PDE8B 3319/4885HSD17B10 2334/4885
US-20230183216-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES PIR, CYP3A43, CYP1A2 ATM 2879/4885PDE8B 3915/4885HSD17B10 2713/4885
US-20060024330-A1 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors DHPS, DUT, CDKN1A ATM 2851/4885PDE8B 1154/4885HSD17B10 1308/4885
US-20060264449-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 ATM 1102/4885PDE8B 2993/4885HSD17B10 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.